Inappropriateness of fresh frozen plasma for abnormal coagulation tests

S Pybus, A MacCormac, A Houghton, V Martlew, J Thachil
1Medical Student, School of Medicine, University of Liverpool; 2Specialist Transfusion Practitioner, Department of Transfusion Science, Royal Liverpool University Hospital; 3Consultant Haematologist, Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK

ABSTRACT
Background: There is increasing evidence to suggest that the use of fresh frozen plasma (FFP) as a prophylaxis to bleeding is ineffective. However, a high proportion of FFP transfusions still occur in non-bleeding patients despite the high risk of adverse events. The aim of the study was to assess compliance with current prophylactic FFP guidelines at a large tertiary centre.

Methods: Data were collected retrospectively over a 16-month period from May 2010 to August 2011. Information collected included patient characteristics, indications for and details of FFP use, and the ordering of coagulation screens before and after transfusion.

Results: Over this period, FFP was used in a total of 573 transfusion episodes, 88 of which were prophylactic. This use deviated from the British Committee for Standards in Haematology guidelines in three main areas: indications for FFP use (89%), dose prescribed (49%) and the measurement of prothrombin time (PT) and activated partial thromboplastin time (APTT) after transfusion (66%).

Conclusions: There were no significant differences in compliance with guidelines between different hospital departments, suggesting a culture of widespread inappropriate FFP use and a general lack of understanding among clinicians. Physician training and increased enforcement of existing guidelines could reduce FFP usage and expenditure.

KEYWORDS Coagulation, plasma, transfusion

DECLARATION OF INTERESTS No conflicts of interest declared.

INTRODUCTION

Fresh frozen plasma (FFP) has been used in the prophylaxis and treatment of patients with coagulopathy and bleeding. However, in recent years, there is an increasing evidence base to suggest that FFP use as prophylaxis in patients with abnormal coagulation tests who are not bleeding is ineffective and often inappropriate.1 Despite this, the levels of FFP use in the UK have not fallen and an estimated 33–43% of transfusions have been noted to occur in cases where bleeding is not suspected.2,3

The use of plasma and plasma-derived products should always follow a careful assessment of anticipated benefit vs risk. Although pathogen-inactivated products have reduced the risk of transfusion-transmitted infections, other adverse effects like transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload continue to pose problems in those who receive FFP.4,5 Transfusion-related acute lung injury is the leading cause of mortality following blood transfusion, with an estimated prevalence of 8% among the intensive care population.6,7 Such risks associated with this blood product highlight the importance of adhering to guidelines outlining the appropriate use of FFP and the role of coagulation testing both before and after transfusion.

Although the British Committee for Standards in Haematology (BCSH) guidelines describe only a limited role for FFP in liver biopsy, it is often used prior to other invasive procedures, such as laparotomy, central line insertion and endoscopy.1 This is despite some previous studies demonstrating that such procedures can be safely performed in patients with an abnormal coagulation screen.7 Although prothrombin time (PT) and activated partial thromboplastin time (APTT) may be useful in identifying individuals who may have inherited bleeding disorders, they are not accurate predictors of bleeding during invasive procedures or surgery.8–12 However PT and APTT are currently the only routinely measured indicators of coagulation with which clinicians can assess response to prophylactic FFP transfusion.

This paper aims to explore the use of FFP as a prophylactic measure to correct abnormal coagulation tests at a large tertiary centre. Therefore a key aim is to determine physician compliance in ordering coagulation...
screens before and after transfusion, as required by current guidelines. We will describe the indications stated for FFP use, and analyse how these patterns compare to the rest of the UK and other reports of inappropriate use from previous years.

METHODS

Data were collected retrospectively using a hospital database. We looked at records from a 16-month period, from 1 May 2010 to 30 August 2011. It should be noted that this centre does not provide services in paediatrics, cardiothoracic surgery, obstetrics or gynaecology. The data collection followed the approval for the study from the regional audit committee. Patient reports for each transfusion episode were examined to determine inclusion or exclusion, using the criteria detailed below.

Inclusion criteria

1. Clear indication of FFP to be used as prophylaxis on patient request forms directly preceding transfusion episode.
2. Reports indicative of an invasive procedure having been performed within six hours after the transfusion episode.

Exclusion criteria

1. ‘Bleeding’ stated on any patient request form in the six hours prior to transfusion episode.
2. ‘Plasmapheresis’ or ‘plasma exchange’ on any patient request forms in the six hours prior to transfusion.
3. New onset decrease in haemoglobin below reference range for this Trust (below 133 g/L for males or 118 g/L for females), within six hours prior to transfusion.
4. More than four units of FFP used and/or multiple transfusion episodes documented in a patient’s recent clinical records. High volumes of transfusion indicate use in massive haemorrhage, while multiple transfusion episodes may indicate plasma exchange. In both these settings, plasma infusion has been shown to be extremely worthwhile.

The following information was extracted for each transfusion episode:

1. Patient characteristics, limited to sex and date of birth.
2. Specialty ward to which FFP was ordered.
3. Indication for FFP use, or in the absence of a clear indication, the related disease process.
4. Number of units of FFP used.
5. Date and time of FFP use.
6. PT and APTT recorded less than 24 hours prior to transfusion.
7. PT and APTT recorded less than eight hours after transfusion.
8. Patient death within 48 hours of transfusion.

Twenty-four hours was selected as an acceptable time frame for the measurement of a coagulation screen to assess the presence and severity of a coagulopathy before transfusion. Eight hours was established for the recording of a coagulation screen after transfusion as this is the half-life of factor VII, the shortest half-life of the procoagulant factors. The normal range for PT at this centre is 9–13 seconds, and 25–36 seconds for APTT. Finally, the data were analysed to determine the appropriateness of the transfusions by indication and to describe clinician compliance in monitoring coagulation before and after transfusion.

RESULTS

A total of 1,673 units of FFP were administered in 573 transfusion episodes over the 16-month period. Of these, 264 units (16%) were used in 88 transfusion episodes (15.4%) as prophylaxis to bleeding. The numbers of transfusion episodes and mean number of units of FFP administered by indication is given in Table 1. In these 88 transfusion episodes, 49 treated males while 39 treated females. The median age of these patients was 56 years (range: 23–87 years). Three patients died within 48 hours of receiving FFP. Two were critical care patients, one with urosepsis and renal failure, and the other suffering from alcoholic liver disease (ALD). The third patient had chest drainage performed on a medical ward. The causes of these deaths could not be elucidated from the database used.

The distribution of indications for FFP use in different clinical settings is given in Table 2. The majority of patients with an unknown indication for transfusion were from critical care (n=13). This patient subset was typically noted to have either multiple organ failure or respiratory failure alone. However, suspected disseminated intravascular coagulation (DIC) and sepsis were also noted on patient request forms. One patient in this group had an initial PT of 107.8 s, implying FFP use related to warfarin overdose. Unfortunately not enough information was available to determine a definitive indication for FFP transfusion.
in only 30 and 26 of the remaining 87 transfusions, respectively. There were no statistically significant differences between coagulation screen compliance levels for each indication ($\chi^2 = 6.00, p = 0.740$) (Figure 1). However, patients undergoing ascitic drainage were the least likely to receive a post-transfusion coagulation screen (9%) compared to 50% of patients with alcoholic liver disease and pre-operative patients.

The majority of FFP requests were made to medical wards (Figure 2). Use in gastroenterology predominated, making up almost half of transfusion episodes on medical wards (17 of 40). Indications stated for FFP use in gastroenterology were ascitic drains (n=3), ALD-related (n=3), biliary procedures (n=3), chest drains (n=2), liver biopsy (n=2), pancreatic pseudocyst procedure (n=2), pelvic drain (n=1), and suspected DIC (n=1). No significant differences were found in compliance with post-transfusion coagulation screens by location ($\chi^2 = 2.34, p = 0.672$).

### Table 1

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of transfusion episodes</th>
<th>Proportion of all transfusion episodes</th>
<th>Mean number of units of FFP administered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown</td>
<td>18</td>
<td>20.5%</td>
<td>2.89</td>
</tr>
<tr>
<td>Pre-operative</td>
<td>14</td>
<td>15.9%</td>
<td>2.86</td>
</tr>
<tr>
<td>Ascitic drain</td>
<td>11</td>
<td>12.5%</td>
<td>2.73</td>
</tr>
<tr>
<td>Alcoholic liver disease</td>
<td>10</td>
<td>11.4%</td>
<td>2.90</td>
</tr>
<tr>
<td>Line insertion</td>
<td>9</td>
<td>10.2%</td>
<td>3.56</td>
</tr>
<tr>
<td>Other drain</td>
<td>8</td>
<td>9.0%</td>
<td>3.13</td>
</tr>
<tr>
<td>Biopsy</td>
<td>6</td>
<td>6.82%</td>
<td>3.67</td>
</tr>
<tr>
<td>Chest drain</td>
<td>6</td>
<td>6.82%</td>
<td>3.00</td>
</tr>
<tr>
<td>Disseminated intravascular coagulation</td>
<td>3</td>
<td>3.41%</td>
<td>3.33</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>3.41%</td>
<td>2.00</td>
</tr>
</tbody>
</table>

### Table 2

<table>
<thead>
<tr>
<th>Indication</th>
<th>Medical ward</th>
<th>Critical care</th>
<th>Surgical ward</th>
<th>Post-op care</th>
<th>Emergency Department</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown</td>
<td>5</td>
<td>13</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pre-operative</td>
<td>5</td>
<td>1</td>
<td>6</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Ascitic drain</td>
<td>7</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Alcoholic liver disease</td>
<td>5</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Line insertion</td>
<td>1</td>
<td>5</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Other drain</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Biopsy</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Chest drain</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Disseminated intravascular coagulation</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

The numbers of transfusion episodes and mean number of units of FFP administered by setting is given in Table 3. A standard dose of FFP is considered to be 10–15 mL/kg with FFP packs averaging around 300 mL. However...
48% of transfusion episodes under study involved only one or two units, which is a sub-therapeutic dose for most adults (less than 30 kg) (Figure 3). Where FFP is given, this must be at a therapeutic dose.

Of the 30 patients with a PT recorded after transfusion, 25 had a decrease in PT following FFP but only one returned to within normal limits. The remaining five patients had an increased PT following FFP. Of these patients, three had surgery, therefore an increased PT could be explained by development of sepsis or other surgical complications. In these 30 patients, 20 had a decreased APTT following FFP with four correcting to within normal limits. The characteristics of the patients where FFP led to correction of coagulation screen to within normal limits is given in Table 4. In one episode, there was no change in APTT after FFP and in five episodes, APTT had increased following transfusion. Again, three of these patients had surgery, therefore sepsis or other surgical complications could explain their increased APTT.

**DISCUSSION**

Despite an increasing volume of evidence challenging the prophylactic use of FFP, use outside current guidelines remains widespread. We found a lack of compliance with current guidelines in three main areas: indications for FFP use, dose prescribed, and the recording of a coagulation screen after transfusion.

The proportion of transfusion episodes for prophylaxis against bleeding at this centre (15%) is lower than that
reported on a national level in 2008 (43%). It appears that since 2008, inappropriate use of FFP in reversal of warfarin therapy has been curtailed. However, its use related to liver disease remains high, comprising 13% of transfusion episodes at this centre compared to the 19% previously reported. After accounting for the differences in patient population, the use of FFP in all other indications appears to have remained constant since 2008. A total of 89% of prophylactic transfusion episodes at this centre were for indications stated outside of those approved by the BCSH. The remaining 11% (related to ALD), may be within current guidelines if the transfusion had preceded liver biopsy. However, this is not supported by evidence as PT and APTT do not reflect the haemostatic state of patients with liver disease, implying that FFP prophylaxis may not always be necessary.

The high number of prophylactic transfusion episodes occurring in critical care is also a matter of concern. Studies have shown that vitamin K deficiency is present in 25% of the intensive care population and is the most common cause of coagulopathy in this patient group. This can be treated by vitamin K supplementation which

| TABLE 4 Characteristics of patients where FFP led to correction of coagulation screen to within normal limits. Analysis from one patient who normalised the PT and four patients who normalised the APTT |
|---|---|---|---|---|---|---|
| Corrected measure | PT prior to FFP(s) | PT after FFP(s) | APTT prior to FFP(s) | APTT after FFP(s) | Quantity of FFP received (units) | Setting | Indication |
| PT | 16.2 | 13.0 | 67.6 | 52.5 | 4 | Medical ward | Hepatic abscess drainage (‘other drain’) |
| APTT | 24.5 | 19.2 | 43.8 | 33.3 | 4 | Critical care | Abdominal drainage related to pancreatitis (‘other drain’) |
| APTT | 19.2 | 14.2 | 44.2 | 30.6 | 4 | Medical ward | |
| APTT | 51.0 | 25.7 | 42.5 | 32.5 | 4 | Emergency department | ALD related (‘ALD’) |
| APTT | 22.4 | 16.7 | 38.0 | 32.9 | 2 | Critical care | Sepsis related (‘unknown’) |

PT = prothrombin time; APTT = activated partial thromboplastin time; ALD = alcoholic liver disease
may prevent the need for FFP at a later stage. Despite this, many centres do not routinely give vitamin K to critical care patients.

A standard dose of FFP is considered to be 10–15 mL/kg with FFP packs averaging around 300 mL. However, we noted that many of the patients received a sub-therapeutic dose of FFP. Despite the low dose, even a small amount of plasma can be considered to expose the patient to risks of adverse reaction without therapeutic benefit. Three patients died within 48 hours of receiving a prophylactic transfusion. Although the role of FFP in these deaths cannot be confirmed, it is a reminder of the high risks associated with its use.

There is also poor compliance with guidelines in performing coagulation screens after FFP transfusion. Previous studies have demonstrated a lack of understanding among clinicians, with many believing that FFP will correct PT and APTT and therefore reduce the risk of bleeding. However little evidence exists to support either of these assumptions. Where FFP transfusion is used to correct coagulopathy, PT and APTT should be measured following transfusion to determine the extent of any improvement before the planned procedure takes place. However, only 34.5% of patients had post-transfusion coagulation screening performed. There were no significant differences in compliance with the post-transfusion coagulation screening between each indication, or between different locations, suggesting a culture of widespread inappropriate use of FFP among clinicians, and their general lack of understanding.

The financial implications of inappropriate FFP use are also significant. It costs this Trust £27.66 per unit. Therefore the cost incurred from FFP transfusion outside current guidelines in this study can be estimated at £6,500. Although the quoted price is purely the cost per bag, there are several other factors including manpower, laboratory equipment and reagents and administrative costs in addition to the hospital staff and bed time which has not been taken into consideration but will add much more to the ‘total’ cost for FFP use. This was highlighted in a recent paper by Shander and colleagues. Using an activity-based costing (ABC) model, they showed that blood costs have been underestimated and stringent control of blood utilisation being necessary to reduce expenditure. In this context, it is also important to note that FFP is a limited resource and therefore should be used with care and within existing guidelines. In addition, although FFP contains several of the coagulation factors, virus-inactivated plasma-derived concentrates have been developed for the management of patients who have congenital or acquired bleeding disorders (except factor V deficiency). For this reason, in many countries, except for the extremely rare coagulation factor V deficiency, all other patients requiring clotting factors are given specific concentrates like factor VIII or IX or prothrombin complex concentrates which contains factors II, VII, IX and X.

Our study suggests that FFP transfusion does not reliably correct PT and APTT values. However due to the high proportion of missing coagulation screens, robust conclusions cannot be drawn about the effectiveness of FFP in correcting PT and APTT. Another limitation of this study is the use of patient request forms for data collection. The data were often of poor quality and difficult to interpret. As a result, the number of transfusions in non-bleeding patients not receiving plasma exchange but of an unknown indication is high (20%).

CONCLUSION

Fresh frozen plasma is associated with higher rates of inappropriate use than any other blood product. Several studies have indicated that inadequate training is to blame for this. A reluctance to adhere to the guidelines has also been identified as a contributing factor to the high number of inappropriate FFP transfusions, with over 46.5% of physicians being reported as non-compliant in one study. One interventional study reported an 80% reduction in FFP usage and reduced inpatient mortality following physician training and enforcement of pre-existing FFP guidelines. Such measures could be of benefit in this centre. More must be done to ensure that FFP transfusion occurs within current guidelines, especially those regarding indication, dose, and repeated coagulation screening. Recent studies have attempted this in different settings (including paediatrics) and confirmed the ongoing inappropriate use of FFP for abnormal coagulation screening.
REFERENCES


